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Background: An estimated 2.5 million children were living with HIV/AIDS at the end of 2009, 2.3 million (92%)
in sub-Saharan Africa. Without treatment, a third of children with HIV will die of AIDS before their first birthday,
half dying before two years of age. Hence, this study aimed to assess magnitude and predictors of mortality
among children on Antiretroviral Therapy (ART) at a referral hospital in North-West Ethiopia.
Methods: Institution based retrospective follow up study was carried out among HIV-positive children from January
1st, 2006 - March 31st, 2011. Information on relevant variables was collected from patients’ charts and registries.
Life table was used to estimate the cumulative survival of children. Log rank tests were employed to compare
survival between the different categories of the explanatory variables. Multivariate Cox proportional hazards
model was fitted to identify predictors of mortality.
Results: A total of 549 records were included in the analysis. The mean age at initiation of treatment was 6.35
±3.78 SD years. The median follow up period was 22 months. At the end of the follow up, 41(7.5%) were dead and
384(69.9%) were alive. Mortality was 4.0 deaths per 100 child-years of follow-up period. The cumulative probabilities
of survival at 3, 6, 12, 24, and 60 months of ART were 0.96, 0.94, 0.93, 0.92 and 0.83 respectively. Majority (90.2%)
of the deaths occurred within the first year of treatment. Absence of cotrimoxazole preventive therapy (adjusted
hazard ratio [AHR] = 4.74, 95% CI: 2.17, 10.34), anaemia (haemoglobin level < 10gm/dl) (AHR=2.44, 95% CI: 1.26,
4.73), absolute CD4 cell count below the threshold for severe immunodeficiency (AHR=2.24, 95% CI: 1.07, 4.69)
and delayed or regressing developmental milestones at baseline (AHR=6.31, 95% CI: 2.52, 15.83) were predictors of
mortality.
Conclusions: There was a high rate of early mortality. Hence, starting ART very early reduces disease progression
and early mortality; close follow up of all children of HIV-positive mothers is recommended to make the diagnosis
and start treatment at an earlier time before they develop severe immunodeficiency.
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Globally, the HIV pandemic created an enormous chal-
lenge to the survival of mankind. By the end of 2008, of
the 33.4 million people living with HIV/AIDS worldwide,
15.7 million were women and 2.1 million were children
under 15 years of age [1]. An estimated 2.5 million chil-
dren were living with HIV at the end of 2009 with 92%
in sub-Saharan Africa. The number of children receiving
ART increased but still more than 2 million HIV-
positive children were in need of treatment by 2010 [2].
The number of children under 15 years of age receiving
ART increased by 29% between 2008 and 2009. Children
represent 6.8% of people receiving ART and 8.7% of
those in need [3].
HIV-infected infants and children now survive to ado-
lescence and adulthood. The challenges of providing
HIV care are evolving into the challenges of providing
both acute and chronic, lifelong care. Recent extensive
investments in expanding HIV/AIDS treatment in low-
and middle-income countries had resulted a marked
improvement in ART coverage from 7% in 2003 to 42%
in 2008 [4].
HIV develops very rapidly among infants and children.
Without treatment, half of children with HIV will die of
AIDS before their second birthday and one third before
year one. In 2009, there were 260,000 deaths attributed
to HIV in under-15 years children, most of which could
have been prevented by early diagnosis and effective
treatment. By the same year, only 29% of the 1.27 million
children in need of ART in low- and middle-income
countries were receiving it [5]. Despite the high risk of
early mortality in HIV-infected children, the average age
at initiation of therapy in resource-limited settings
remained high. For example, in a cohort of more than
2,400 HIV-infected children in West Africa, the average
age at start of ART was 4.9 years [6]. Data emerging
since the publication of the 2006 WHO recommenda-
tions for ART in infants and children approves that early
initiation of ART is life-saving [7].
Ethiopia launched the fee-based ART in 2003 and free
ART in 2005, delivered as part of the comprehensive
HIV/AIDS care [8]. Though evaluation of mortality of
HIV-positive children on ART is vital for ART program
effectiveness, few studies were conducted so far. There-
fore, estimating mortality and its predictors among HIV-
positive children would provide an input for policy
makers to revise the guidelines of pediatric ART initi-
ation. This will also have implication for program plan-
ners and decision makers at various stages of the HIV/
AIDS care and support program.
Methods
Institution based retrospective follow up study was car-
ried out among HIV-positive children. The study wasconducted at Felege Hiwot Referral Hospital (Bahir Dar,
Ethiopia) from January 1st 2006 - March 31st 2011.
Bahirdar is the capital city of Amhara National Regional
State and it is located 562 kilo meters from Addis
Ababa, capital of Ethiopia. Apart from other services,
Felege Hiwot Referral Hospital provides chronic HIV
care (both pre-ART and ART) services. There were 1092
children ever enrolled into the HIV care and support
program and 661 had ever started ART in the hospital
till March 2011.
ART clinic setup and clinical protocol
The ART clinical services are provided by a team com-
prising of doctors and nurses. At this clinic, HIV-
positive children will be screened for opportunistic
infections (OIs), evaluated for clinical staging and eligi-
bility for ART by an ART physician/nurse. ART initi-
ation for infants and children was according to the 2007
guidelines for pediatric HIV/AIDS care and treatment in
Ethiopia [9] after thorough adherence preparation and
counselling. It is determined clinically (WHO stage)
and/or immunologically (CD4 count or percentage).
Follow-up appointment depends on the child’s condition
ranging from every fortnight to monthly basis.
All HIV-positive children on care and support follow
up who had started ART at Felege Hiwot referral hos-
pital pediatric ART clinic were included in the study.
Data were entered and cleaned using EPI info version
3.5.1 and analyzed by SPSS version 16.0 statistical pack-
age for windows. Life table was used to estimate the
cumulative survival of children and log rank tests were
employed to compare survival between explanatory vari-
ables. Bivariate Cox-proportional hazards model was
fitted for all explanatory variables. Those variables with
p-value ≤ 0.2 in the bivariate analysis were fitted to the
multivariate Cox-proportional hazards model. Backward
LR method was used to select variables for the final
model. Hazard ratio with its 95% confidence interval and
p-values were used to measure strength of association
and identify statistical significant result. P-value < 0.05
was considered as statistically significant association.
Operational definitions
CD4 count below the threshold for severe immunodefi-
ciency was classified according to the child’s age (for
infants CD4<1500/mm3, 12–35 months <750/mm3, 36–
59 months <350/mm3 and ≥5 years <200/mm3) [9].
Adherence to ART was classified into good, fair or
poor by the percentage of drug dosage calculated from
the total monthly doses of ART drugs. (Good >95%, fair
85-94%, poor <85%).
Developmental milestone, using the WHO window
of achievement, for six gross motor milestones was
assessed and classified as: delayed, if a child fails to
Table 1 Baseline socio-demographic characteristics of
Children on ART at Felege Hiwot referral hospital,
January 1st, 2006 - March 31st, 2011
Variable Frequency Percent (%)
Age
< 1yr 22 4.0
1-5 yr 197 35.9







Care giver of the child (n=452)
Parents 377 83.4
Guardian 19 4.2
In Orphanage centers 10 2.2
Grand parents 36 8.0
Sibling 10 2.2
Orphan hood (n = 438)
Mother and father alive 241 55.0
Maternal orphan 102 23.3
Paternal orphan 38 8.7
Double orphan 57 13.0
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has been attained for age, otherwise normal [9].
Underweight was defined as weight for age Z-score < −2
SD for under-five children and BMI for age Z-score < −2
SD for older children.
Anaemia was defined as having haemoglobin level of
less than 10 mg/dl.
Ethical considerations
Ethical clearance was assured from Institutional Review
Board of School of Public Health, College of Medicine
and Health Sciences, University of Gondar. Permission
letter was obtained from the hospital administration.
As this was a retrospective study using secondary data,
informed consent from individual patients was not
obtained. Names and unique ART numbers were not
included in the study.
Results
Baseline socio-demographic profile of study participants
Of the 574 children’s records reviewed, 549 were
included in the final analysis. The mean age was 6.4 ±
3.8SD years and 60.1% were older than 5 years. About
half (52.1%) were males and two third (66.5%) were from
urban areas (Table 1).
Baseline clinical and immunological profile of
study participants
Majority (96.7%) had appropriate developmental mile-
stones at ART initiation. Nearly two third (68.5%) chil-
dren started ART at an advanced stage of the disease i.e.
WHO clinical stage III or IV. About half of them
(52.6%) had absolute CD4 count below the threshold for
severe immunodeficiency. About half (52.3%) were on
cotrimoxazole prophylactic therapy, 82.5% were under-
weight and 19.8% had anaemia (<10 gm/dl) (Table 2).
For 12.5% of children on ART, first drug regimen was
changed. Drug side effects (63.2%) followed by develop-
ing tuberculosis while on ART (20.1%) were the main
reasons for changing initial regimen. More than half
(53%) of the regimens were changed within the first
three months and nearly three quarters (71.2%) within
six months of ART initiation. A total of 49 (8.9%) chil-
dren developed drug side effects, mainly (49%) anaemia
followed by Nevirapine associated rash. One hundred
sixty five (30.1%) children had one or more major
OIs. Tuberculosis was the leading OI (40%) followed
by pneumonia (21.8%), oral candidiasis (13.3%) and
Pneumocystis jirovecii pneumonia (9.1%).
Mortality after initiation of ART
The median follow up period was 22 months (ranging
between 1 and 62 months, IQR=28 months). At the end
of follow up, 384 (69.9%) children were alive, 32 (5.8%)were lost from follow up, 92 (16.8%) were transferred
out to other facilities and 41(7.5%) were reported dead.
Hence, the risk of death was calculated to be 4.0 per 100
child-years of observation. Concerning the time of death,
26 (63.4%), 31 (75.6%) and 37 (90.2%) of the deaths
occurred within the first three, six and twelve months
of ART initiation respectively. One in ten deaths (9.8%)
occurred after one year of ART initiation. Little informa-
tion was available about the possible cause(s) of death.
The mean survival time was 56.5 months (95% CI:
54.62, 58.38 months). For estimation of survival prob-
ability two models were used. The first model used
confirmed dead cases (n=41) as events (real case
assumption) and the second model assumed the worst
scenario (worst case assumption) in which both dead
and lost cases (n=73) were considered as events. The cu-
mulative probabilities of survival at 3, 6, 12, 24 and 60
months of ART initiation were 0.96, 0.94, 0.93, 0.92 and
0.83 respectively in the real case assumption while it was
0.93, 0.92, 0.90, 0.88 and 0.71 respectively while assum-
ing the worst case scenario (Figure 1).
Predictors of mortality after initiation of ART
Cox regression revealed that not receiving cotrimoxazole
preventive therapy at baseline and delayed or regressing
developmental history were predictors of mortality to
Table 2 Baseline clinical and immunological status of
Children on ART at Felege Hiwot referral hospital,
January 1st, 2006 - March 31st, 2011
Variable Frequency Percent (%)
ART eligibility criteria
WHO clinical stage 9 1.6
Immunological/CD4Count 35 6.4
Both clinical and immunologic 505 92.0





Kaletra based 3 0.6




CD4 count below the threshold 289 52.6
























OIs during follow up
Yes 165 30.1
No 384 69.9
Side effect during follow up(526)
Yes 49 8.9
No 477 86.9
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absolute CD4 count below the threshold for severe im-
munodeficiency were significantly and independently
associated with mortality of HIV-positive children. How-
ever, age, sex, presence of OI, baseline nutritional status
and WHO clinical stage were not significant predictors
of mortality.
Accordingly, if the child was not on cotrimoxazole
preventive therapy at baseline, there was a 4.74 (95% CI:
2.17, 10.34) times increased risk of death. Children with
low haemoglobin level were almost two and half times
(AHR = 2.44, 95 CI%: 1.26, 4.73) at risk of death
compared to their counterparts. Similarly, children with
absolute CD4 count below the threshold for severe
immunodeficiency were 2.24 (95% CI: 1.07, 4.69) times
at risk of death. A delayed or regressing developmental
milestone at initiation of ART 6.31(95 CI%: 2.52, 15.83)
times higher risk of death compared to those with
appropriate developmental milestone (Table 3).
Discussion
At the end of the follow up, there were 7.5% death and
5.8% lost from follow up. The mortality rate was 4/100
child-years of follow up. This was comparable to previ-
ous studies in Ethiopia [10,11] and other countries in
sub-Saharan Africa [12-16]. In Jimma University hospital
[10], 7.3% died and 71.9% were alive at the end of follow
up. However, mortality was lower in this study compared
to a study from Kenya (8.4%) [17]. This could be
explained in three ways. Firstly, the difference in the
study period as there were changes in the treatment and
care of children on ART through time. Secondly, the
Kenyan study was conducted on a lower sample size
(n=149) and may be an inadequate estimate. Thirdly,
it may be due to the health care system changes in
Ethiopia such as decentralization, task shifting and dele-
gation of HIV/AIDS services to low- and mid-level
health care providers. Similar to many studies in sub
Saharan Africa [10-14,16] where 69% - 89% of deaths
occurred in the first six months after ART initiation,
in this study more than three quarter of the deaths
occurred in the first six months of ART.
This early peak in mortality might be due to delayed
ART initiation which increases the risk of severe malnu-
trition, drug toxicity and immune reconstitution inflam-
matory syndrome. Moreover, as evidenced from this
study, two third of the patients were at WHO clinical
stage III or IV and half of them had absolute CD4 count
below the threshold for severe immunodeficiency at
ART initiation. The study setting was a referral hospital
which provides ART and hence children with advanced
stages of the disease may be referred in for initiation.
The possible reason for increased survival with duration
of ART could be the result of progressive increase in
Figure 1 Kaplan Meier survival curve among Children on ART at Felege Hiwot referral hospital, January 1st, 2006 - March 31st, 2011.
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the decrease in viral load across time.
As can be noted from the findings of multivariate Cox
regression analysis, predictors of mortality were absence
of cotrimoxazole preventive therapy, low baseline
haemoglobin, absolute CD4 count below the threshold
for severe immunodeficiency and delayed or regressing
baseline developmental milestone(s). World Health
Organization recommends starting cotrimoxazole pre-
ventive therapy for all exposed infants at four-to-six
weeks of age even before the diagnosis of HIV-infection
[18] which is again supported by the result of this study
where baseline cotrimoxazole preventive therapy was
strongly related to lower risk of mortality. Similarly, data
from a large randomized clinical trial in Zambia [19]
provided evidence that daily cotrimoxazole preventive
therapy is effective in reducing morbidity, mortality, and
hospitalizations in HIV-infected children regardless of
CD4 value. Cotrimoxazole preventive therapy prevents
the development of very serious and fatal OIs [19] and
hence it contributes to lower mortality and morbidity.
The other predictor of mortality was CD4 count below
the threshold for severe immunodeficiency. This finding
was also supported by several studies [7,11-13,20-22].
Lower haemoglobin level (below 10gm/dl) at initiation
of ART was another predictor of mortality. Several
studies revealed anaemia as an independent predictor
of mortality among children on ART [7,11,12,17,21].
Anaemia, a common complication of pediatric HIVinfection, is commonly associated with disease progres-
sion and death. Late presentation of children for treat-
ment has several associated problems as evidenced from
this study (68.4% presented with advanced clinical stage
and 82.5% with underweight). Starting ART very early
reduces disease progression and early mortality [7].
Having delayed or regressing developmental milestone
at initiation of ART was strong predictor of mortality.
Delayed or regressing developmental milestone at ART
initiation may further complicate the immunological and
clinical recovery.
The main limitation of this study is that it includes
fewer young children and over-represents children diag-
nosed at a late stage of the disease. This made compari-
sons with other similar studies difficult. As data were
collected from secondary sources, incompleteness was
inevitable and it was difficult to assess clinical and im-
munological responses. Mortality might be underesti-
mated in this study, since lost to follow-up might also
include those died without being reported. The study
also failed to assess possible causes of death.
Conclusions
There was a high rate of early mortality. The mean age
at the start of ART was also high. If the child was not on
cotrimoxazole preventive therapy at baseline, there exists
a higher risk of mortality. Additionally, low haemoglobin
level (less than 10gm/dl), absolute CD4 cell count below
the threshold for severe immunodeficiency and delayed
Table 3 Multivariate Cox regression analysis of predictors of mortality among Children on ART at Felege Hiwot referral
hospital, January 1st, 2006 - March 31st, 2011
Variable Survival status Crude HR (95% CI) Adjusted HR (95% CI)
Died Censored
Age
< 1yr 4 18 1
1-5 yr 10 187 0.25(0.08, 0.79) *
5 -15 yr 27 303 0.38(0.13, 1.09) *
Sex
Male 17 269 0.66 (0.35, 1.22) *
Female 24 239 1
OIs
Yes 20 145 2.01 (1.09, 3.72) *
No 21 363 1
Cotrimoxazole preventive therapy
Yes 8 279 1 1
No 33 229 4.89(2.26,10.59) 4.74 (2.17, 10.34)
Developmental history
Appropriate 34 497 1 1
Delayed/regressing 7 11 10.13(4.43, 23.1) 6.31(2.52, 15.83)
WHO staging
I/II 8 165 0.28(0.11, 0.72) *
III 23 294 0.43(0.21, 0.91) *
IV 10 49 1
Haemoglobin (n = 520)
<10gm/dl 15 88 2.87(1.5, 5.5) 2.44 (1.26, 4.73)
≥10gm/dl 24 393 1 1
Nutritional status
Underweight 39 414 3.89(0.94, 16.1) *
Normal 2 94 1
CD4 cell count
CD4 count below the threshold 30 259 2.55(1.28, 5.1) 2.24(1.07, 4.69)
CD4 count above the threshold 11 249 1 1
* Non significant from the multivariate Cox regression (Backward LR method).
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predictors of mortality.
Hence, starting ART very early reduces disease
progression and early mortality; close follow up of all
children of HIV-positive mothers is recommended to
make the diagnosis and start treatment at an earlier
time before they develop severe immunodeficiency.
Cotrimoxazole prophylaxis should be initiated as early
as possible to all eligible infants and children to reduce
early mortality. Children with low haemoglobin level
and delayed development shall get proper diagnosis and
care such as nutritional interventions to reduce the risk
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